TY  - GEN
AU  - Azuma,Junichi
AU  - Hasunuma,Tomoko
AU  - Kubo,Masanori
AU  - Miyatake,Masaya
AU  - Koue,Toshiko
AU  - Higashi,Koushi
AU  - Fujiwara,Tsutomu
AU  - Kitahara,Sachiko
AU  - Katano,Tamiki
AU  - Hara,Sumiko
TI  - The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
SN  - 1432-1041
PY  - 2012///0504
KW  - Adult
KW  - Antipsychotic Agents
KW  - adverse effects
KW  - Aripiprazole
KW  - Biotransformation
KW  - Cytochrome P-450 CYP2D6
KW  - genetics
KW  - Cytochrome P-450 CYP2D6 Inhibitors
KW  - Cytochrome P-450 CYP3A
KW  - Cytochrome P-450 CYP3A Inhibitors
KW  - Drug Interactions
KW  - Enzyme Inhibitors
KW  - Fluvoxamine
KW  - Genetic Association Studies
KW  - Half-Life
KW  - Humans
KW  - Japan
KW  - Male
KW  - Metabolic Clearance Rate
KW  - drug effects
KW  - Paroxetine
KW  - Piperazines
KW  - Polymorphism, Genetic
KW  - Quinolones
KW  - Serotonin 5-HT2 Receptor Antagonists
KW  - Selective Serotonin Reuptake Inhibitors
KW  - Young Adult
N1  - Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s00228-011-1094-4
ER  -